GlassScriptPhysician profile
Michael D Baldinger
NPI 1255606596
$3,878.72
in general payments reported to CMS, 2019-2025
14 companies · $994 in 2025
The $994 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $150 · 2021: $301 · 2022: $485 · 2023: $769 · 2024: $830 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $741.59 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $706.41 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $552.57 | 2019-2025 | Precision 1, Total30, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $472.49 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $364.07 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $337.70 | 2021-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $182.89 | 2019-2021 | |
| Abbvie INC. | $144.74 | 2023-2024 | |
| Dompe US, INC. | $137.30 | 2021-2023 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $104.85 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $49.50 | 2023 | |
| Harrow Eye, LLC | $47.82 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $19.83 | 2023 | |
| Sight Sciences, INC. | $16.96 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baldinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.